Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Anticancer Res. 2015 Oct;35(10):5219–5223.

Figure 1.

Figure 1

Changes in suppressor of cytokine signaling 3 [SOCS3] gene expression. A: Expression of SOCS3 increased significantly with time on treatment (p=0.02 using one-way analysis of variance). Mean expression at 9, 12 and >14 months was significantly higher than at baseline, as assessed by Dunnett's multiple comparisons test. Horizontal bars represent median±standard deviation. p<0.05 was considered statistically significant. B: SOCS3 expression was significantly higher in patients with the Janus kinase 2 V617F mutation.